| 臺大學術典藏 |
2022-09-15T01:08:50Z |
Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: The PACT phase Ia/Ib trial
|
Patnaik A.; Yap T.A.; Chung H.C.; de Miguel M.J.; Bang Y.-J.; Chia-Chi Lin; Su W.-C.; Italiano A.; Chow K.H.; Szpurka A.M.; Yu D.; Zhao Y.; Carlsen M.; Schmidt S.; Vangerow B.; Gandhi L.; Xu X.; Bendell J. |
| 臺大學術典藏 |
2021-04-23T05:56:26Z |
Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC
|
Awad M.M.;Gadgeel S.M.;Borghaei H.;Patnaik A.;Chih-Hsin Yang;Powell S.F.;Gentzler R.D.;Martins R.G.;Stevenson J.P.;Altan M.;Jalal S.I.;Panwalkar A.;Gubens M.;Sequist L.V.;Saraf S.;Zhao B.;Piperdi B.;Langer C.J.; Awad M.M.; Gadgeel S.M.; Borghaei H.; Patnaik A.; CHIH-HSIN YANG; Powell S.F.; Gentzler R.D.; Martins R.G.; Stevenson J.P.; Altan M.; Jalal S.I.; Panwalkar A.; Gubens M.; Sequist L.V.; Saraf S.; Zhao B.; Piperdi B.; Langer C.J. |
| 國立成功大學 |
2021 |
Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: The PACT phase Ia/Ib trial
|
Patnaik, A.;Yap, T.A.;Chung, H.C.;de, Miguel M.J.;Bang, Y.-J.;Lin, C.-C.;Su, W.-C.;Italiano, A.;Chow, K.H.;Szpurka, A.M.;Yu, D.;Zhao, Y.;Carlsen, M.;Schmidt, Schmidt S.;Vangerow, B.;Gandhi, L.;Xu, Xu X.;Bendell, J. |
| 臺大學術典藏 |
2020-05-26T09:26:44Z |
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
|
Keynote-021 Investigators;Gandhi L;Raftopoulos H;Ge Y;Fiore J;Awad M.M;Sequist L.V;Gubens M;Chih-Hsin Yang;Panwalkar A;Jalal S.I;Stevenson J.P;Martins R.G;Gentzler R.D;Powell S.F;Patnaik A;Papadimitrakopoulou V.A;Borghaei H;Gadgeel S.M;Langer C.J; Langer C.J; Gadgeel S.M; Borghaei H; Papadimitrakopoulou V.A; Patnaik A; Powell S.F; Gentzler R.D; Martins R.G; Stevenson J.P; Jalal S.I; Panwalkar A; CHIH-HSIN YANG; Gubens M; Sequist L.V; Awad M.M; Fiore J; Ge Y; Raftopoulos H; Gandhi L; KEYNOTE-021 investigators |
| 臺大學術典藏 |
2020-05-26T09:26:44Z |
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
|
Keynote-021 Investigators;Gandhi L;Raftopoulos H;Ge Y;Fiore J;Awad M.M;Sequist L.V;Gubens M;Chih-Hsin Yang;Panwalkar A;Jalal S.I;Stevenson J.P;Martins R.G;Gentzler R.D;Powell S.F;Patnaik A;Papadimitrakopoulou V.A;Borghaei H;Gadgeel S.M;Langer C.J; Langer C.J; Gadgeel S.M; Borghaei H; Papadimitrakopoulou V.A; Patnaik A; Powell S.F; Gentzler R.D; Martins R.G; Stevenson J.P; Jalal S.I; Panwalkar A; CHIH-HSIN YANG; Gubens M; Sequist L.V; Awad M.M; Fiore J; Ge Y; Raftopoulos H; Gandhi L; KEYNOTE-021 investigators |
| 臺大學術典藏 |
2020-05-26T09:26:25Z |
Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non?�small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study
|
Papadimitrakopoulou V.;Raftopoulos H;Saraf S;Bachman R;Sequist L.V;Chih-Hsin Yang;Hauke R;Gubens M;Villaruz L.C;Patnaik A;Borghaei H;Gandhi L;Langer C.J;Stevenson J.P;Gadgeel S.M; Gadgeel S.M; Stevenson J.P; Langer C.J; Gandhi L; Borghaei H; Patnaik A; Villaruz L.C; Gubens M; Hauke R; CHIH-HSIN YANG; Sequist L.V; Bachman R; Saraf S; Raftopoulos H; Papadimitrakopoulou V. |
| 臺大學術典藏 |
2020-05-26T09:26:25Z |
Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non?�small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study
|
Papadimitrakopoulou V.;Raftopoulos H;Saraf S;Bachman R;Sequist L.V;Chih-Hsin Yang;Hauke R;Gubens M;Villaruz L.C;Patnaik A;Borghaei H;Gandhi L;Langer C.J;Stevenson J.P;Gadgeel S.M; Gadgeel S.M; Stevenson J.P; Langer C.J; Gandhi L; Borghaei H; Patnaik A; Villaruz L.C; Gubens M; Hauke R; CHIH-HSIN YANG; Sequist L.V; Bachman R; Saraf S; Raftopoulos H; Papadimitrakopoulou V. |
| 臺大學術典藏 |
2020-05-26T09:26:24Z |
24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non?�Small Cell Lung Cancer
|
Borghaei H;Langer C.J;Gadgeel S;Papadimitrakopoulou V.A;Patnaik A;Powell S.F;Gentzler R.D;Martins R.G;Stevenson J.P;Jalal S.I;Panwalkar A;Chih-Hsin Yang;Gubens M;Sequist L.V;Awad M.M;Fiore J;Saraf S;Keller S.M;Gandhi L.; Borghaei H; Langer C.J; Gadgeel S; Papadimitrakopoulou V.A; Patnaik A; Powell S.F; Gentzler R.D; Martins R.G; Stevenson J.P; Jalal S.I; Panwalkar A; CHIH-HSIN YANG; Gubens M; Sequist L.V; Awad M.M; Fiore J; Saraf S; Keller S.M; Gandhi L. |
| 臺大學術典藏 |
2020-05-26T09:26:24Z |
24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non?�Small Cell Lung Cancer
|
Borghaei H;Langer C.J;Gadgeel S;Papadimitrakopoulou V.A;Patnaik A;Powell S.F;Gentzler R.D;Martins R.G;Stevenson J.P;Jalal S.I;Panwalkar A;Chih-Hsin Yang;Gubens M;Sequist L.V;Awad M.M;Fiore J;Saraf S;Keller S.M;Gandhi L.; Borghaei H; Langer C.J; Gadgeel S; Papadimitrakopoulou V.A; Patnaik A; Powell S.F; Gentzler R.D; Martins R.G; Stevenson J.P; Jalal S.I; Panwalkar A; CHIH-HSIN YANG; Gubens M; Sequist L.V; Awad M.M; Fiore J; Saraf S; Keller S.M; Gandhi L. |
| 臺大學術典藏 |
2020-05-26T09:26:22Z |
Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
|
Raftopoulos H; Patnaik A.; Saraf S; Fiore J; Su W.-C; Papadimitrakopoulou V.A; Wu C.-L; Sequist L.V; Gadgeel S.M; CHIH-HSIN YANG; Chih-Hsin Yang;Gadgeel S.M;Sequist L.V;Wu C.-L;Papadimitrakopoulou V.A;Su W.-C;Fiore J;Saraf S;Raftopoulos H;Patnaik A. |
| 臺大學術典藏 |
2020-05-26T09:26:22Z |
Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
|
Raftopoulos H; Patnaik A.; Saraf S; Fiore J; Su W.-C; Papadimitrakopoulou V.A; Wu C.-L; Sequist L.V; Gadgeel S.M; CHIH-HSIN YANG; Chih-Hsin Yang;Gadgeel S.M;Sequist L.V;Wu C.-L;Papadimitrakopoulou V.A;Su W.-C;Fiore J;Saraf S;Raftopoulos H;Patnaik A. |
| 臺大學術典藏 |
2020-05-25T07:35:29Z |
Phase i and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies
|
Chia-Chi Lin; Beeram M; Rowinsky E.K; Takimoto C.H; Ng C.M; Geyer Jr. C.E; Denis L.J; De Bono J.S; Hao D; Tolcher A.W; Rha S.-Y; Jolivet J; Patnaik A. |
| 臺大學術典藏 |
2020-05-25T07:35:28Z |
Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients
|
Ng C.M; Patnaik A; Beeram M; Chia-Chi Lin; Takimoto C.H. |
| 國立成功大學 |
2019 |
Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
|
Yang, J.C.-H.;Gadgeel, S.M.;Sequist, L.V.;Wu, C.-L.;Papadimitrakopoulou, V.A.;Su, W.-C.;Fiore, J.;Saraf, Saraf S.;Raftopoulos, H.;Patnaik, A. |
| 臺大學術典藏 |
2009 |
Phase i study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors
|
Tolcher A.W.; Chen H; Dancey J.E; Takimoto C.H; O'Rourke P; Yeh I.-T; Chia-Chi Lin; Calvo E; Papadopoulos K.P; Patnaik A; Sarantopoulos J; Mita A.C; Preston G.G; Mita M.M; Rodon J; Mays T |
